Transcatheter bicaval valve implantation in patients with symptomatic severe tricuspid regurgitation: Initial experience and 2-year follow-up in a Chilean center

Aim: To determine the safety and clinical impact of TricValve two years after implantation. Background: Tricuspid Regurgitation (TR) causes a decrease in functional capacity with an associated increased mortality. In patients unsuitable for percutaneous orthotopic strategies, TricValve bicaval valve implantation is an option. Patients and methods: Retrospective study of a cohort of 6 patients with severe TR and NYHA CF III-IV despite medical therapy who underwent TricValve implantation between January and December, 2022. The primary endpoint was the device safety and functional status of patients 2 years after implantation. Results: Six patients were included. Mean age was 66 ± 10 years, 50% were women. TriScore (risk scoring model for isolated tricuspid valve surgery) was 7.0 ± 2.4. Improvement was achieved at 2 years in all patients as measured by improvement in CF (p=0.024), NT-ProBNP (p=0.028), renal function (p=0.068) and consequent reduction in diuretic dose (p 0.028). No deaths were reported during follow-up and no rehospitalizations for heart failure were reported. Conclusion: TricValve implantation is safe and associated with clinical improvements at 2 years. Keywords